Literature DB >> 11285042

Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention.

M Laakso1.   

Abstract

Type 2 diabetes increases the risk of cardiovascular disease (CVD) two- to fourfold compared with the risk in non-diabetic subjects. Although type 2 diabetes is associated with a clustering of risk factors (small, dense low-density lipoprotein [LDL] particles, low high-density lipoprotein [HDL] cholesterol, high triglycerides, elevated blood pressure, obesity, central obesity, hyperinsulinaemia, hyperglycaemia, etc.), the cause for an excess risk of CVD remains unknown. Recent drug treatment trials have indicated that the lowering of total and LDL cholesterol and blood pressure is similarly beneficial in diabetic and non-diabetic subjects. The treatment of hyperglycaemia reduces micro- and macrovascular complications in type 2 diabetic patients. Beta-blocking agents, angiotensin-converting enzyme inhibitors, aspirin, and thrombolytic therapy are also effective in the treatment of CVD amongst diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285042     DOI: 10.1046/j.1365-2796.2001.00789.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  73 in total

1.  Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers.

Authors:  G F Ferraccioli; E Gremese
Journal:  Ann Rheum Dis       Date:  2004-03-17       Impact factor: 19.103

2.  [Characteristics of therapy of acute myocardial infarction in diabetes].

Authors:  W Motz; W Kerner
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

Review 3.  The Wnt signaling pathway: aging gracefully as a protectionist?

Authors:  Kenneth Maiese; Faqi Li; Zhao Zhong Chong; Yan Chen Shang
Journal:  Pharmacol Ther       Date:  2008-02-11       Impact factor: 12.310

4.  Can Time Efficient Exercise Improve Cardiometabolic Risk Factors in Type 2 Diabetes? A Pilot Study.

Authors:  Anders Revdal; Siri M Hollekim-Strand; Charlotte B Ingul
Journal:  J Sports Sci Med       Date:  2016-05-23       Impact factor: 2.988

Review 5.  Cardiovascular risk in children and adolescents with type 2 diabetes mellitus.

Authors:  Christopher Prendergast; Samuel S Gidding
Journal:  Curr Diab Rep       Date:  2014-02       Impact factor: 4.810

6.  Implication of circulating omentin-1 level on the arterial stiffening in type 2 diabetes mellitus.

Authors:  Hye Jin Yoo; Soon Young Hwang; Ho Cheol Hong; Hae Yoon Choi; Sae Jeong Yang; Kwan Woo Lee; Moon Suk Nam; Yong Soo Park; Jeong Taek Woo; Young Seol Kim; Kyung Mook Choi; Sei Hyun Baik
Journal:  Endocrine       Date:  2013-03-27       Impact factor: 3.633

Review 7.  A "FOXO" in sight: targeting Foxo proteins from conception to cancer.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  Med Res Rev       Date:  2009-05       Impact factor: 12.944

Review 8.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

Review 9.  Therapeutic promise and principles: metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543

10.  The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender.

Authors:  Marjukka Hyvärinen; Jaakko Tuomilehto; Tiina Laatikainen; Stefan Söderberg; Mats Eliasson; Peter Nilsson; Qing Qiao
Journal:  Cardiovasc Diabetol       Date:  2009-03-24       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.